Phosphatidylcholine catabolic process

Across TCGA pan-cancer cohorts, RNA activity of the Phosphatidylcholine catabolic process pathway differs between tumor and matched normal tissue in 13 of the 18 cancer types tested.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as KIRP and COAD, show the opposite pattern, with lower activity in tumor tissue.

KIRP, KIRC, and COAD show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
KIRP	All	II,III,IV	−0.060	<.001	11	view →
KIRC	All	II,III,IV	+0.029	<.001	9	view →
COAD	All	All	−0.031	<.001	7	view →
LUSC	Female	All	−0.070	<.001	6	view →
BRCA	All	All	−0.068	<.001	6	view →
STAD	All	All	+0.050	.005	4	view →
LUAD	All	All	−0.024	.002	4	view →
ESCA	All	II,III,IV	+0.095	.044	2	view →
READ	Male	All	−0.040	.016	2	view →
PRAD	All	All	+0.036	<.001	2	view →
CHOL	All	All	−0.055	.010	1	view →
HNSC	Male	III,IV	+0.025	.033	1	view →

Pink = more active in tumor, green = less active in tumor. Showing the 12 strongest of 13 lineages.

GO:0034638–KIRP

Open the KIRP breakdown →